Clinical Research Directory
Browse clinical research sites, groups, and studies.
Oral Verapamil Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
Sponsor: Ain Shams University
Summary
Type 1 diabetes (T1D) in children involves autoimmune destruction of pancreatic ß- cells, leading to insulin deficiency. Verapamil is an L-type calcium channel blocker that has been used for decades to treat hypertension and certain cardiac conditions. Recent research has revealed its potential as a ß- cell-protective agent. Hence this study will evaluate the effect of once-daily oral verapamil on pancreatic ß- cell reserve , glycemic metrics and daily insulin requirements in children and adolescents with T1D.
Official title: Efficay and Safety of Oral Verapamil on Glycemic Metrics and ß-cell Reserve Among Newly Diagnosed Children and Adolescents With Type 1 Diabetes
Key Details
Gender
All
Age Range
10 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
70
Start Date
2026-08-20
Completion Date
2027-03-20
Last Updated
2026-09-04
Healthy Volunteers
No
Conditions
Interventions
Verapamil oral
active comparator
Placebo
placebo comparator
Locations (1)
Ain Shams University
Cairo, Egypt